Search Results (258)

Background: Facial atrophic acne scars have a significant impact on patients’ psychosocial well-being and remain a therapeutic challenge. Existing treatments options are frequently limited by modest efficacy and adverse effects. The combination of Polynucleotide High-Purification Technology (PN HPT™) and hyaluronic acid (HA) represents a novel bioregenerative strategy aimed at improving dermal remodelling and overall skin quality. Methods: This six-month, prospective, real-world study evaluated the efficacy and safety of Newest^® (Mastelli S.r.l., Sanremo, Italy), a sterile intradermal gel containing highly purified polynucleotides (10 mg/mL) and HA (10 mg/mL). Eligible participants, aged 20–60 years with moderate-to-severe atrophic facial post-acne scars, underwent four treatment sessions in two-week intervals. Efficacy was assessed using the Acne Scar Assessment Scale (ASAS) and Global Aesthetic Improvement Scale (GAIS) at three and six months, while safety was monitored throughout the study. Results: A total of 62 patients (32 Caucasian, 30 Asian; 19 males, 43 females; mean age: 36.6 years) completed the study. At three and six months, 46.8% showed at least a one-grade reduction in ASAS score with respect to the baseline. Patient-reported GAIS indicated that 54.8% perceived an improvement in scar appearance, aligning with investigator assessments. Only one mild, transient adverse event (wheal formation) occurred, which resolved spontaneously without intervention. Conclusions: In this real-world study, treatment with Polynucleotide High-Purification Technology (10 mg/mL) combined with HA (10 mg/mL) was associated with observable improvementin atrophic facial acne scars, with an excellent safety and tolerability profile. These findings support the potential of polynucleotide-based therapies for use as well-tolerated options for managing moderate-to-severe atrophic acne scarring, while the need for further controlled studies to confirm efficacy is also acknowledged. Full article

Intense training loads alter the skin microbiome and defence mechanisms in athletes, yet adaptation profiles remain insufficiently characterised. This study evaluated the relationships between skin bacterial microbiome structure, antimicrobial activity, dermcidin levels, and acne severity in male professional hockey players compared with amateur athletes and non-athletes. One hundred men (18–57 years) were examined and allocated to six subgroups by exercise intensity and acne status. Microbiota composition was assessed by culture-based methods and MALDI-TOF identification, antimicrobial activity measured spectrophotometrically, dermcidin quantified by ELISA, and sweat proteome characterised by HPLC-MS. Staphylococcus epidermidis and Micrococcus luteus predominated in all groups. Exercise intensity, rather than acne, was the main determinant of total bacterial colonisation, which increased approximately tenfold from non-athletes to professional hockey players. In non-athletes, higher antimicrobial activity correlated with greater acne severity, whereas in professionals this relationship was absent and dermcidin levels showed an inverse association with acne severity. Proteomic analysis identified 17 polypeptides; dermcidin and prolactin-inducible protein were dominant in all groups, and calprotectin (S100-A8/A9) was detected exclusively in healthy professionals. Full article

Background/Objectives: Microbial dysbiosis is implicated with a pathogenic role in both irritable bowel syndrome (IBS) and several dermatological conditions. Yet, few studies have assessed a potential overlapping epidemiologic association. We aimed to assess the 1-year prevalence of common dermatologic conditions following an initial IBS diagnosis and to evaluate the reverse association using reciprocal analyses. Methods: We conducted a retrospective study using TriNetX. Patients aged 18–50 with no history of inflammatory bowel disease, celiac disease, or infectious intestinal disease were matched 1:1 to healthy controls by demographics and comorbidities. The primary outcome was the prevalence of acne vulgaris, psoriasis, atopic dermatitis, hidradenitis suppurativa, rosacea, vitiligo, alopecia areata, and urticaria 1 year after IBS diagnosis, measured using Odds Ratios (ORs) and 95% confidence intervals. To confirm bidirectionality, reciprocal analyses were performed. Results: Over a 1-year period, IBS patients were less likely to have acne vulgaris (OR: 0.78, CIs: 0.75–0.80) and vitiligo (OR: 0.78, CIs: 0.64–0.95) compared to those without. IBS patients were more likely to have psoriasis (OR: 1.14, CIs: 1.08–1.21), hidradenitis suppurativa (OR: 1.11, CIs: 1.03–1.20), rosacea (OR: 1.10, CIs: 1.03–1.18), and urticaria (OR: 1.27, CIs: 1.21–1.34) compared to healthy controls. No association was found for atopic dermatitis or alopecia areata. In the reciprocal analysis, alopecia areata patients (OR: 0.76, CIs: 0.64–0.90) had a lower prevalence of IBS compared to healthy controls. IBS was shown to occur more frequently in patients with psoriasis (OR: 1.15, CIs: 1.07–1.23), rosacea (OR: 1.23, CIs: 1.15–1.31), and urticaria (OR: 1.06, CIs: 1.01–1.12) compared to healthy controls. No association was seen in patients with acne, atopic dermatitis, hidradenitis suppurativa, and vitiligo. Conclusions: IBS shows a bilateral positive overlapping association with psoriasis, rosacea, and urticaria. Hidradenitis suppurativa showed a positive association only among IBS patients, with no reciprocal relationship. Moreover, our findings suggest that acne and vitiligo were inversely associated with IBS; however, this was not supported in our reciprocal analysis. Although no association was initially found between IBS and alopecia areata, the reciprocal analysis suggests a potential inverse association. No association was seen with atopic dermatitis bilaterally. Clinicians who treat these disorders should be aware of the potential bidirectional association. Full article

Acne vulgaris (AV) is a chronic inflammatory skin disorder, and cytokines such as interleukin-17 (IL-17), interleukin-19 (IL-19), and C-reactive protein (CRP) are thought to contribute to its immunopathogenesis. This study investigated serum and salivary levels of CRP, IL-17, and IL-19 in patients with AV and examined their relationship with disease severity. A total of 99 participants aged 15–30 years were classified into Control (n = 28), Moderate AV (n = 43), and Severe AV (n = 28) groups using the Global Evaluation Acne (GEA) Scale. Serum and saliva samples were analyzed using ELISA and immunoturbidimetric assays. Statistical comparisons and correlation analyses were performed. Serum IL-17 levels were significantly higher in the control group compared to both acne groups (p < 0.05), with no gender-related differences. Salivary cytokine levels showed no significant group differences. However, IL-17 and IL-19 were strongly correlated in both saliva (r = 0.672, p < 0.005) and serum (r = 0.538, p < 0.005) across the entire study population. Serum and salivary CRP levels showed no significant differences between groups. In contrast to previous reports, our study found lower serum IL-17 levels in AV patients compared to healthy controls, challenging the assumption of its purely pro-inflammatory role and suggesting a potential compensatory or regulatory immune mechanism to maintain homeostasis. These findings may also reflect distinct physiological pathways between systemic interleukin activity and localized skin inflammation. Although salivary cytokine levels did not differ significantly among groups, strong intra-sample correlations highlight their interaction and support saliva’s potential as a non-invasive tool for monitoring immune activity. Full article

Background: Acne vulgaris is a common inflammatory disorder with significant clinical and psychosocial impacts. Medium-depth chemical peels are increasingly used to manage both active acne lesions and atrophic acne scars. This study aimed to quantitatively assess the clinical effectiveness of a novel multimodal medium-depth chemical peel regimen, yellow peel, in improving acne severity and scar depth, as well as skin hydration and sebum production in patients with mild to moderate facial acne. Methods: Twenty patients (17 women and 3 men) aged 20–25 with mild to moderate acne vulgaris underwent two sessions of yellow peel treatment at four-week intervals. The peel protocol combined glycolic acid, salicylic acid, and a multi-acid mask containing retinol, azelaic, phytic, kojic, and salicylic acids. Clinical outcomes were evaluated at baseline, four weeks after the first peel, and two months after the second peel. Assessments included the Investigators Global Assessment (IGA), inflammatory lesion count, 3D scar depth analysis, skin hydration (corneometer), and sebum secretion (sebumeter). Results: Yellow peel treatment significantly reduced acne severity, with an 85% decrease in inflammatory lesion counts and over 20% reduction in scar depth. Skin hydration improved significantly across all facial regions, and sebum secretion decreased substantially, enhancing skin barrier function and seboregulation. Statistical analysis confirmed the treatment’s efficacy with sustained improvements two months post-final peel. Conclusions: The yellow peel protocol is an effective and well-tolerated adjunct therapy for managing mild to moderate acne and atrophic acne scars. By combining exfoliative, anti-inflammatory, antibacterial, sebostatic, and depigmenting agents, this multimodal approach delivers comprehensive skin improvement. Further large-scale, controlled studies are recommended to confirm long-term safety and efficacy. Full article

A comparative study of alpha-induced reactions on cobalt isotope with the predictions by COMPLET code is presented for nine excitation functions, ⁵⁹Co(α,p5n)⁵⁷Ni, ⁵⁹Co (α,p6n)⁵⁶Ni, ⁵⁹Co(α,2pn)⁶⁰Co, ⁵⁹Co(α,3pn)⁵⁹Fe, ⁵⁹Co(α,αn)⁵⁸Co, ⁵⁹Co(α,α2n)⁵⁷Co, ⁵⁹Co(α,α3n)⁵⁶Co, ⁵⁹Co(α,2αn)⁵⁴Mn, and ⁵⁹Co(α,2α3n)⁵²Mn. The experimental values were taken from the EXFOR data base. Theoretical cross-sections were calculated using initial exciton number n₀ = 4 (4p0h) and level density parameter a (=ACN/10) globally. While several reactions showed excellent agreement with experimental data, others displayed a notable discrepancy. This is because of the limitations of the COMPLET code to take the alpha emission in a pre-equilibrium phase. Full article

Background and Objectives: Acne vulgaris is a prevalent chronic inflammatory skin condition affecting adolescents and young adults worldwide. Increasing concern regarding antimicrobial resistance has renewed interest in microbiome-modulating therapies, including oral probiotics. This systematic review and meta-analysis evaluated the efficacy and safety of oral probiotic supplementation for acne vulgaris using contemporary random-effects methods. Materials and Methods: Following PRISMA 2020 guidelines, we searched PubMed, Embase, Web of Science, and ClinicalTrials.gov through November 2025 without language restrictions. Eligible studies were double-blind randomized controlled trials (RCTs) comparing oral probiotics with placebo or standard therapy for ≥4 weeks and reporting quantitative acne severity outcomes. Risk of bias was assessed using RoB 2.0. Standardized mean differences (SMDs) were pooled using restricted maximum likelihood (REML) with Hartung–Knapp adjustment. Heterogeneity was summarized using I², τ² (95% CI), and 95% prediction intervals. Adverse events were extracted. Results: Three RCTs (n = 231) met eligibility criteria. Pooled analysis suggested a modest reduction in inflammatory lesion counts favoring probiotics (SMD −0.57; 95% CI −0.94 to −0.21), although heterogeneity was substantial (I² = 72%; τ² = 0.11). The 95% prediction interval (−1.25 to 0.11) indicated that future studies may plausibly observe no meaningful effect. Sensitivity analyses using the DerSimonian–Laird estimator produced comparable results. All trials reported good short-term tolerability with no serious adverse events. Risk of bias was low in two trials and of some concern in one. Certainty of evidence was rated low to moderate. Conclusions: Oral probiotics may modestly reduce acne severity as a generally safe, antibiotic-sparing adjunct; however, the current evidence base is small and heterogeneous, and the certainty of effect remains low-to-moderate. Larger, standardized RCTs are required before firm clinical recommendations can be made. Registration: PROSPERO CRD420251181388. Funding: This research received no external funding. Full article

Background: Hypochlorous acid (HOCl) is an integral component of the human innate immune system. It possesses antimicrobial properties and is available in solution, dermal spray, and scar gel forms. Objectives/Methods: This review presents data from studies on the clinical use of HOCl in various specialties, including dermatology, surgery, dentistry, ophthalmology, and rhinology. Results: Due to its anti-inflammatory/antimicrobial/immunomodulatory and healing properties, HOCl is advantageous in treating various skin disorders: ulcus cruris (and wound care), diabetic ulcers, atopic dermatitis, seborrheic dermatitis, pruritus, acne vulgaris, etc. Also, the application of a HOCl spray/gel after surgical procedures may prevent infection, reduce inflammation, and accelerate healing. HOCl is also effective and safe for the prevention and treatment of hypertrophic and keloid scars. Growing evidence shows a broader role for HOCl in limiting cancer cell survival and slowing tumor growth. It is also important in treating various viral infections like SARS-CoV-2 (coronavirus), influenza, and herpes, thereby helping to prevent the spread of aerosols. In addition, since HOCl is an endogenous compound naturally present in mammals with a high safety profile, it may be an effective bacterial disinfectant in dental waterlines. In ophthalmology, adjuvant treatment with HOCl ophthalmic spray can reduce the duration of antibiotic/corticosteroid use, even in severe blepharitis. To fully harness the protective/therapeutic properties of HOCl, future advancements will rely on the development of new chemical compounds and sophisticated pharmaceutical formulations. Conclusions: The majority of clinical studies have confirmed that HOC1 is useful in therapy, although the results are not entirely consistent. Further research is essential to optimize HOCl dosing and to develop controlled-release systems aimed at maximizing its anti-inflammatory and photoprotective effects while minimizing tissue irritation and damage. Full article

Background: Acne vulgaris is a multifactorial disease with significant clinical and psychosocial impacts. Methods: The purpose of this study was to evaluate the efficacy of a combination therapy including oral isotretinoin and a non-ablative 675 nm red-light laser compared with laser monotherapy. Thirteen young patients with active facial acne of varying severity were enrolled and divided into two groups: Seven subjects received laser monotherapy treatment (RT group), while six underwent combined laser and isotretinoin therapy (RTI group). The laser protocol consisted of six weekly sessions, with a 5-point pain scale used to monitor tolerability. Standardized photographs were obtained at baseline and at a 3-month follow-up after the last treatment. Each patient completed the Acne Radar Questionnaire, and lesion severity was assessed using the Global Evaluation Acne (GEA) scale. Results: All patients completed the study without adverse events. Scores from the Acne Radar Questionnaire improved in both groups, while the GEA scale demonstrated a significant reduction in lesion severity, confirmed by photographic comparison. Pain was reported as mild in most cases, and no discontinuations occurred. Conclusions: These findings indicate that the 675 nm laser is a safe and effective therapeutic option for acne vulgaris, with isotretinoin addition resulting in more rapid and pronounced clinical improvement. Full article

The human skin microbiome, defined as a multifaceted ecosystem comprising bacteria, fungi, viruses, and mites, plays a pivotal role in maintaining skin homeostasis and regulating immune responses. In recent years, an increasing amount of evidence has illuminated the considerable influence exerted by microbiomes on the pathophysiology of dermatological ailments. This review provides a comprehensive synthesis of contemporary findings concerning the microbiome’s role in acne, aging, hyperpigmentation, and hair disorders, while also addressing the emerging concept of the gut–skin axis and how it could interfere in these skin disorders. Alterations in microbial composition, referred to as dysbiosis, have been associated with inflammatory processes and barrier dysfunction, thereby contributing to the severity and chronicity of diseases. Distinct microbial profiles have been identified as correlating with specific skin conditions. For instance, variations in Cutibacterium acnes phylotypes have been associated with the development of acne, whereas alterations in Corynebacterium and Staphylococcus species have been linked to the processes of aging and pigmentation patterns. Furthermore, the composition of the microbiome is examined in relation to its impact on cosmetic outcomes. It also engages with increasing interest in the modulation of microbiota through the topical application of bioactive compounds. The incorporation of prebiotics, probiotics, and postbiotics into cosmetic formulations constitutes a novel strategy aimed at enhancing skin health. In the domain of dermatological therapies, postbiotics have emerged as a significant class of substances, particularly due to their remarkable stability, safety, and immunomodulatory properties. These characteristics position them as promising candidates for incorporation into dermatological treatments. Recent studies have underscored the significance of microbiome-informed strategies within the domains of therapeutic and preventive dermatology, emphasizing the potential of such approaches to positively influence patient outcomes. As our understanding of this field continues to evolve, skin microbiomes are poised to emerge as a pivotal area of focus in the realm of personalized skin care and treatment. This development presents novel and innovative approaches for the management of skin conditions, characterized by enhanced specificity and efficacy. Full article

Acne is a multifactorial skin condition characterized by an infection in the pilosebaceous units in the skin. Patients with acne suffer from comedones, papules, pustules and nodules or cysts in severe cases. These clinical features might cause disfigurmentation, depression, anxiety and significantly impact the quality of life of patients. Systemic and continuous exposure of antibiotics put patients at risk of developing systemic toxicity, bacterial resistance and gut dysbiosis. Microneedles offer an innovative approach of providing targeted topical delivery of minocycline while insuring efficient permeation through skin layers. Methods: minocycline microneedles were formulated using casting method and characterized for insertion ability, mechanical strength, drug content, antibacterial activities, deposition and dissolution behavior using ex vivo full-thickness rat skin. Results: Insertion tests confirmed effective skin penetration and mechanical integrity with only 9.5% height reduction. Drug content was 673.06 ± 5.34 µg/array. Dissolution occurred within 2 min in skin, indicating user-friendly wear time. Ex vivo Franz diffusion studies showed 26% of the drug deposited into the skin, significantly higher (p = 0.0068) than the 18.3% that permeated through it. Antibacterial testing revealed strong activity against S. aureus, S. epidermidis, and C. acnes, with MIC values < 0.146 µg/mL and MBC values ranging from 9.375–18.75 µg/mL. Conclusions: The result of this research demonstrate that minocycline microneedles effectively deliver minocycline into the skin highlighting their potential as a safer and more efficient alternative for acne therapy. Full article

Background: Hidradenitis suppurativa (HS) is a chronic, recurrent skin disease that significantly impairs patients’ quality of life both physically and mentally. It often requires a complex treatment process. Laser therapy, which is highly effective and well-tolerated, is an effective alternative to pharmacological treatment. This review aimed to synthesize information on laser therapy for HS, highlighting its clinical outcomes. In the current management guidelines for hidradenitis suppurativa, laser therapy is listed as one of the recommended procedural treatment options, applicable at different stages of disease severity (Hurley I–III). Methodology: This systematic review was conducted using the PubMed and Embase databases, regardless of publication year, in accordance with the PRISMA guidelines. Applied key search terms were: “laser AND (hidradenitis suppurativa OR acne inversa)”. A total of 26 relevant studies were identified, and their data were extracted. Results: The CO₂ laser is mainly used in advanced stages of the disease (Hurley II–III). It allows effective removal of lesions with a minimal risk of relapse and a good aesthetic effect. The Nd:YAG (neodymium-doped yttrium aluminum garnet; Nd: Y₃Al₅O₁₂) laser is effective at various stages of the disease (Hurley I–III) by reducing inflammation and destroying hair follicles, thereby reducing disease symptoms. IPL (intense-pulse light) therapy, or the combination of IPL with radiofrequency (RF), known as LAight^®, delivers significant clinical improvement and enhanced quality of life, especially in less advanced cases. The diode laser works precisely and deeply, leading to the selective destruction of hair follicles and fistulas. The Alexandrite laser (755 nm) also limits hair follicle occlusion and is particularly effective in patients with lighter skin phototypes. Conclusions: In modern dermatology, laser therapy is a reliable treatment for HS, contributing to effective regression of the disease at all stages. Combination strategies seem to improve clinical outcomes and enable a more personalized approach to HS, which is essential as various factors influence therapeutic efficacy. Further, larger-scale studies are needed to validate long-term outcomes and establish clinical guidelines. Full article

Acne vulgaris is a multifactorial disease with high heritability, but the genetic determinants of severity remain incompletely defined. This study evaluated 650 individuals genotyped with a 60-single-nucleotide polymorphism (SNP) panel covering immune, lipid, endocrine, and barrier pathways. Acne severity was graded as 1 (n = 193), 2–3 (n = 383), or 4 (n = 74). Single-SNP analysis highlighted associations in loci such as LHCGR (rs13405728), TGF-β2 (rs1159268), FST (rs38055), WNT10A (rs74333950), PIK3R1 (rs10515088), and THADA (rs13429458) and barrier-related variants (FLG, FLG-AS1). Epistasis analysis of 44 quality-controlled SNPs revealed 190 significant interactions (false discovery rate, FDR ≤ 0.10), with TLR4 as the main hub (degree = 22), bridging immune (IL10, TNF), lipid (PNPLA3, APOE), and barrier (FLG-AS1, OVOL1) genes. Polygenic risk scoring (PRS) showed a monotonic increase across severity grades, with Grade 4 displaying higher median scores (0.319) compared to Grade 1 (−0.129) and Grades 2–3 (0.034). Discrimination was modest but consistent (AUC: 0.661 for Grade 4 vs. 1; 0.662 vs. 2–3; 0.679 vs. all others). These results support a framework where microbial sensing, lipid metabolism, and barrier function converge to drive severe acne, underscoring the potential of genetic profiling for risk stratification and precision therapy. Full article

Objectives: Oral isotretinoin remains the most effective therapy for severe acne, but its exceptional efficacy is often accompanied by relatively frequent adverse effects. In this study, we quantified the frequency- and dose-related predictors of clinical and biochemical adverse effects during isotretinoin treatment in routine Polish practice. Methods: The records of 370 patients (mean age: 28 ± 12 years) who began isotretinoin treatment between June 2020 and June 2025 were reviewed. The mean daily isotretinoin and cumulative isotretinoin doses were 23.4 ± 9.1 mg and 88.3 ± 31.5 mg/kg, respectively. The adverse events documented at two-monthly visits were correlated with age and dosing. Lipid, hepatic, thyroid and prolactin panels were compared with age- and sex-matched controls using χ² statistics and odds ratios (ORs). Results: Xerosis (70%), retinoid dermatitis (20%) and cheilitis (15.5%) predominated. Hand eczema rose with higher daily isotretinoin doses (ρ = 0.082; p = 0.037), whereas pruritus declined with greater cumulative isotretinoin exposure (ρ = −0.088; p = 0.037). Retinoid dermatitis was linked to a younger age (ρ = −0.080; p = 0.0286), whereas desquamation increased slightly with age (ρ = +0.083 p = 0.0228). Overall, dyslipidemia was twice as common as in the controls (OR: 2.06; 95% CI: 1.49–2.86; p-value: <0.0001), which was driven by an elevated total cholesterol (OR: 1.93; 95% CI: 1.34–2.77; p-value: 0.0004), LDL (OR: 3.40; 95% CI: 2.26–5.10; p-value: <0.0001) and triglycerides (OR: 1.95; 95% CI: 1.20–3.17; p-value: 0.0062) and decreased HDL (OR: 2.68; 95% CI: 1.75–4.10; p-value: <0.0001). Interestingly, hyperprolactinemia occurred eight-fold more often (OR: 8.42; 95%; 95% CI: 2.97–23.84; p-value: <0.00001). Aminotransferase and TSH elevations were infrequent and statistically non-significant. Conclusions: At moderate cumulative doses, isotretinoin was generally well tolerated; however, clinically relevant lipid and prolactin disturbances were frequent. Routine lipid and endocrine monitoring, early emollient prophylaxis and dose individualization are recommended to ensure safe isotretinoin usage in everyday practice. Full article

Acne vulgaris is a chronic disease that occurs in the pilosebaceous units and ranks eighth in the global prevalence of all diseases. In its severe forms such as pustules, cysts, and nodules, acne can lead to permanent scarring and post-inflammatory hyperpigmentation, which are often difficult to reverse in the short term and significantly affect patients’ psychological well-being and social interactions. Although a variety of pharmacological treatments are available, including retinoids, antibiotics, anti-androgens, benzoyl peroxide, and corticosteroids, the high recurrence rate and limited efficacy in scar prevention highlight the urgent need for innovative therapeutic strategies. Electrospinning technology has recently gained attention for fabricating nanofibrous patches with high porosity, biocompatibility, and biodegradability. These patches can offer antibacterial activity, absorb exudates, and provide mechanical protection, making them promising platforms for acne wound care. This review first outlines the pathophysiology of acne and the biological mechanisms underlying scar formation. We then present an overview of electrospinning techniques, commonly used polymers, and recent advancements in the field. Finally, we explore the potential of electrospun nanofibers loaded with mesenchymal stem cells or exosomes as next-generation therapeutic systems aimed at promoting scarless acne healing. Full article